medical data analytics osteoporosis treatment after vertebral and hip fractures: analysis of a...
Post on 05-Jan-2016
213 Views
Preview:
TRANSCRIPT
Medical Data AnalyticsMedical Data AnalyticsMedical Data Analytics
Osteoporosis Treatment after Vertebral and Hip Fractures: Analysis of a Managed Care Population in the US
Ankita Modi*1, Amber Wilk2, Chun-Po Steve Fan3, Shiva Sajjan1 and Panagiotis Mavros1
1Merck & Co. Inc., 2Virginia Commonwealth University, 3AsclepiusJT LLC
2
Medical Data Analytics
Abstract
Purpose: It is recommended that fractures patients be treated with pharmacological treatment for osteoporosis to mitigate subsequent fracture risk. This study examined osteoporosis treatment use after vertebral or hip fractures in a US managed care population.Methods: A retrospective analysis using i3 Invision Datamart, a large claims database, from January 2003 to June 2012 (study period) was conducted. Women ≥ 50 years of age with vertebral and/or hip fracture during the study period with continuous enrollment 24 months before (pre-index) and 12 months after (post-index) the first fracture (index date) were included. Women with Paget's disease or malignant neoplasms were excluded. Fractures were identified using ICD-9 diagnosis codes. Osteoporosis treatment included bisphosphonates (alendronate, ibandronate, risedronate, zoledronic acid) and non-bisphosphonates (calcitonin, raloxifene, teriparatide, denosumab), which were identified by NDC and HCPCS codes. Charlson comorbidity index (CCI) was used to quantify a patient’s overall comorbid conditions. Pre- and post-index osteoporosis treatment use was assessed by fracture site. Results: 11,433 women ≥ 50 years of age (7,834 vertebral; 3,599 hip fracture) were included in the study. Hip fracture patients were on average older than the ones with vertebral fracture patients (71.3 vs. 66.8 years, p<.001). Hip fracture patients had a significantly higher average CCI than vertebral fracture patients (1.5 vs. 1.3, p<.001). Despite occurrence of fracture, 82.1% of patients did not receive treatment within the 3-month post-index period, and 77% remained untreated at 1-year post-index. The number of hip fracture patients not receiving treatment within 3-month and 1-year post-index periods was significantly higher than that of the vertebral fracture patients (3-month untreated rate: 81.6% vs. 69.4%, p< .001; 1-year untreated rate: 75.0% vs. 62.5%, p<.001). Among those treated within 3-month (1-year) post-index, the average time between fracture and treatment were 13.8 (46.5) and 20.7 (65.4) days for vertebral and hip fracture patients, respectively. Conclusions: This study shows a high rate of undertreatment of osteoporosis with medications after patients experienced vertebral and hip fractures despite treatment recommendations for these high-risk patients. This warrants a need for further education regarding osteoporosis management for patients with prior fractures.
3
Medical Data Analytics
Background & Rationale
Osteoporosis-related fractures are a significant burden to both healthcare systems and patients. They are associated with increased morbidity, disability, mental health issues, and mortality.
It is recommend that patients with osteoporotic fractures be treated with pharmacological treatment for osteoporosis to mitigate subsequent fracture, especially among patients with vertebral or hip fractures
Despite available treatment options, persistent treatment gaps leave fracture patients at increased risk for repeat fractures
• Understanding the characteristics of patients with osteoporotic fracture and their osteoporosis medication use patterns after fracture is critical for the successful management of healthcare costs and osteoporosis
4
Medical Data Analytics
Study Objective
• To examine osteoporosis treatment use after vertebral or hip fractures in a US managed care population.
5
Medical Data Analytics
Methods
• Data Source:
– i3 Invision Datamart database (now known as the Clinformatics™ Data Mart), a large US administrative claims dataset containing medical and pharmacy claims in the study period (Q1 2003-Q2 2012)
6
Medical Data Analytics
Methods (continued)
Study Population•Inclusion Criteria:
– Women 50 years or older who had an vertebral and hip fractures during the index period from January 1, 2005 to June 30, 2011
– Continuous enrollment for at least two years before (baseline) and one year after (follow-up) the first osteoporosis fracture (index date)
– No prior osteoporosis fracture during the two or more years prior to the index date
•Exclusion Criteria:– Paget's disease (ICD-9 code 731.0) ever in the claims
history– Malignant neoplasms in the two years before and one
year after index date
7
Medical Data Analytics
Methods (continued)
Study Design
24 Months Baseline Period
12 Months
Follow-up
Jan 1, ‘05 Jun 30, ‘11
Index Date
Index Period
Jan 1, ‘03 Jun 30, ‘12
8
Medical Data Analytics
Methods (Continued)
• Osteoporosis fractures were assessed based on the following ICD-9 CM diagnosis codes
Fracture Type
ICD-9 CM Code
Vertebral Dorsal & Lumbar: 733.13, 805.2, 805.4Other: 805.0, 805.1, 805.3, 805.6, 805.8, 805.9, 806.xx
Hip Neck of femur: 733.14, 820.xx
9
Medical Data Analytics
Methods (Continued)
•Osteoporosis medications were identified from pharmacy (NDC) and medical claims (J-codes) and included bisphosphonates (alendronate, risedronate, ibandronate, and zoledronic acid), and non-bisphosphonates (calcitonin, raloxifene, teriparatide, and denosumab)
10
Medical Data Analytics
Methods (continued)
• Patient groups based on treatment prior to fracture– Treated at baseline: patients who were prescribed any
osteoporosis medication at any time during the baseline period– Currently treated: patients who were treated at baseline and
whose days of supply overlap the index date• Medication adherence
– A patient was said to be adherent to therapy if the medication possession ratio (MPR) was at least 80%.
– The MPR was calculated as the ratio of the medication days supply over the 24-month baseline and 12-month follow-up period.
• Patient characteristics included – Age at fracture; Charlson comorbidity index; medication
adherence; fall history; use of corticosteroids; estrogen, and NSAIDs; and osteoporosis-related comorbidities
11
Medical Data Analytics
Table 1: Patient Accrual
N= 249, 072
Women ≥1 diagnosis of OP-related fractures in the study period
N = 213,226
Age ≥ 50 as of Index Date (first fracture date)
N = 212,816
Patients without Paget’s disease of the bone
N = 70,084
Patients with 24 months of baseline and 12 months of follow-up continuous eligibility
Patients without malignant neoplasms in the baseline and study period
N = 47,171
Patients with non-vertebral (N=34,396) or with multiple fractures at index ( N=1,342)
Excluded from current analysis
Patients with either vertebral or hip fractures (N=11,433)
Hip (N=3,599)Vertebral (N=7,834)
12
Medical Data Analytics
Results
• 7, 834 women with vertebral and 3,599 women with hip fractures were eligible for inclusion in this study– Women with hip fractures were older than those with
vertebral (71.3 vs. 66.8 years)– More than half of women with vertebral fractures were
between 50 – 69 years– 27.7 % of women with vertebral fractures were treated at
baseline compared to 20.2% of the women with hip fractures
• 15.1% of vertebral and 9.4% of hip fractured women were treated at the time of the fracture (currently treated)
– History of falls of any type was slightly higher among patients with hip than vertebral fractures (8.7% vs. 7.5%)
– Hip fracture women had a significantly higher average CCI than vertebral fracture women (1.5 vs. 1.3)
13
Medical Data Analytics
Table 2: Baseline Characteristics by Fracture Type
Characteristic Vertebral (N=7,834)
Hip (N=3,599)
P-value
Age at Index
Mean Age in Years (SD)66.8 (10.2) 71.3 (9.6) <.0001
Age Group 50-592469 (31.5) 610 (16.9) <.0001
Age Group 60-691901 (24.3) 657 (18.3)
Age Group 70-792563 (32.7) 1651 (45.9)
Age Group 80+901 (11.5) 681 (18.9)
Patients w/ Prior Osteoporosis Diagnosis
2,230 (28.5) 745 (20.7) <.0001
History of Falls of Any Type587 (7.5) 313 (8.7) 0.0264
Baseline Osteoporosis Medication 2,171 (27.7) 727 (20.2) <.0001
Currently Treateda 1,181 (15.1) 338 (9.4) <.0001
Charlson Comorbidity Index – Mean (SD)
1.3 (1.7) 1.5 (1.8) <.0001
14
Medical Data Analytics
Table 3: Concomitant Medications and Comorbid Conditions by Fracture Type
Characteristic Vertebral (N=7,834)
Hip (N=3,599) P-value
Concomitant Medication UseGastroprotective agent
2291 (29.2) 988 (27.5) 0.0491NSAID
3240 (41.4) 1270 (35.3) <.0001Glucocorticoids
2581 (32.9) 839 (23.3) <.0001Estrogens
1467 (18.7) 422 (11.7) <.0001
Comorbid Conditions
Osteopenia1600 (20.4) 506 (14.1) <.0001
Arthritis4808 (61.4) 2151 (59.8) 0.1020
Myocardial Infarction319 (4.1) 168 (4.7) 0.1428
Cerebrovascular Disease1162 (14.8) 731 (20.3) <.0001
Chronic pulmonary Disease2124 (27.1) 857 (23.8) 0.0002
Hypothyroidism1874 (23.9) 747 (20.8) 0.0002
Diabetes1466 (18.7) 757 (21.0) 0.0036
Obesity554 (7.1) 177 (4.9) <.0001
15
Medical Data Analytics
Results (continued)
• The rate of under treatment did not change drastically before and after the fractures, especially when considering the treatment recommendations for patients with vertebral and hip fractures during the study period– Between baseline and follow-up, about 10%
decrease in under treatment rate was observed among vertebral fractured women compared to approximately 5% in women with hip fractures
– The fact that most of the decrease in under treatment is attributed to treatment receipt during the last 9 months of the follow-up is suggestive of a delay in treatment initiation following a vertebral or hip fracture
16
Medical Data Analytics
Figure 1: Under-treatment Rate by Fracture Type
17
Medical Data Analytics
Results (continued)
• Among women treated during the 12 months after fracture:– Majority of women with hip fracture and those with
vertebral fractures (77.1% and 67.4 respectively) received bisphosphonates only therapy
• Women with hip fractures were less adherent to bisphosphonates only therapy as compared to those with vertebral fractures (18.9% vs. 29.2%)
– 7.2 % of women with hip fracture and 12.4% those with vertebral fracture used both bisphosphonate and non- bisphosphonate therapies as a result of switching from one class to another
• 20.6% of women in the hip fracture group being adherent to treatment as compared to 44.4% of those in the vertebral fracture group
– The overall analysis of all women who received treatment after fracture showed that women with hip fractures had lower adherence to therapy compared to those with vertebral fractures (21.2% vs. 29.4%)
18
Medical Data Analytics
Figure 2: Baseline and After Fracture Adherence rate by Fracture Type
aAdherence defined as MPR ≥0.80; bPatients were switched between bisphosphonate and non-bisphosphonate (not concomitant use)
Notes:[1] Baseline adherence rate were calculated among 2,898 patients who were treated at baseline and experienced vertebral or hip fractures [2] Post-fracture adherence rate among 3,834 patients who were treated following vertebral or hip fractures
19
Medical Data Analytics
Table 5: Medication Possession Ratio (MPR) and Adherence to Osteoporosis Medications at Baseline
Women with medication use at Baseline
Characteristic Vertebral (N=2,171) Hip (N=727)
Bisphosphonate use only
Users, n (%) 1607 (74.0) 532 (73.2)
Pre-index MPR, mean (SD) 0.48 (0.32) 0.44 (0.31)
Adherent patients,a n (%) 377 (23.5) 91 (17.1)
Non-Bisphosphonate use only
Users, percentage (n) 361 (16.6) 136 (18.7)
Pre-index MPR, mean (SD) 0.42 (0.33) 0.47 (0.33)
Adherent patients,a n (%) 72 (19.9) 35 (25.7)
Bisphosphonate and Non-Bisphosphonate
use only
Users, n (%) 203 (9.4 ) 59 (8.1)
Pre-index MPR, mean (SD) 0.62 (0.30) 0.56 (0.29)
Adherent patients,a n (%) 83 (40.9) 19 (32.2)
Baseline osteoporosis treatment overall
Pre-index MPR, mean (SD) 0.48 (0.32) 0.46 (0.31)
Adherent patients, n (%) 532 (24.5) 145 (19.9)
aAdherence defined as MPR ≥0.80; bPatients were switched between bisphosphonate and non-bisphosphonate (not concomitant use)
20
Medical Data Analytics
Table 6: Medication Possession Ratio (MPR) and Adherence to Osteoporosis Medications 12 months
After FractureWomen with medication use at post-index
Characteristic Vertebral (N=2,936) Hip (N=898)
Bisphosphonate use only
Users, n (%)1679 (67.4) 692 (77.1)
Post-index MPR, mean (SD) 0.55 (0.31) 0.49 (0.29)
Adherent patients,a n (%) 577 (29.2) 131 (18.9)
Non-Bisphosphonate use only
Users, n (%)594 (20.2) 141 (15.7)
Post-index MPR, mean (SD) 0.45 (0.32) 0.47 (0.30)
Adherent patients,a n (%) 126 (21.2) 29 (20.6)
Bisphosphonate and Non-Bisphosphonate
use only
Users, n (%)
363 (12.4) 65 (7.2)
Post-index MPR, mean (SD) 0.69 (0.26) 0.69 (0.26)
Adherent patients,a n (%) 161 (44.4 ) 30 (20.6)
Post index osteoporosis treatment overall
Post-index MPR, mean (SD) 0.55 (0.31) 0.51 (0.30)
Adherent patientsn (%) 864 (29.4) 190 (21.2)
aAdherence defined as MPR ≥0.80; bPatients were switched between bisphosphonate and non-bisphosphonate (not concomitant use)
bAdherence percent is based on the number of users in each drug class categories
21
Medical Data Analytics
Limitations
• Due to the nature of administrative claims data, inaccuracies associated with coding errors might lead to misclassification of patients
• The analysis relied on prescription claims as a proxy for medication use
• The results are not adjusted for confounders and may be subject to biases
22
Medical Data Analytics
Conclusions • This study demonstrates that, despite treatment
recommendations, a high percent of women remain untreated or are not adherent to therapy after experiencing vertebral and hip fractures.
• Despite being at high risk for repeat fractures, only a 37.5% of vertebral fracture and 25% of hip fractured women received osteoporosis treatment 12 months after fracture– A significant unmet medical need exists among
women experiencing fractures– Novel osteoporotic treatments may provide
additional tools for disease management• Further education regarding osteoporosis
management to both patients and physicians as well as adherence programs may contribute to improved outcomes and lower health care costs.
top related